Figure 7.
The BCKDK inhibitor enhances BCAA catabolism and attenuates IR in DIO mice. DIO mice were treated with the vehicle (Ctrl) or BT2 by oral gavage for 8 weeks (n = 7 mice in each group). We analyzed BCKD activity in various tissues (A), fasting plasma levels of BCAAs (B, left) and BCKAs (B, right), glucose tolerance test results (C), insulin tolerance test results (D), fasting plasma insulin level (E), and body weight (F). *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.0001, all vs. Ctrl. ΚΙC, α-ketoisocaproic acid; KIV, α-ketoisovaleric acid; KMV, α-keto-β-methylvaleric acid.